Consensus Bausch + Lomb Corporation Toronto S.E.

Equities

BLCO

CA0717051076

Market Closed - Toronto S.E. Other stock markets 20:59:50 25/06/2024 BST			5-day change	1st Jan Change
20.35 ^CAD	-0.20%		+1.09%	-10.23%

06-17	Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care"	MT
06-10	Bausch + Lomb Corporation Announces the U.S. Introduction of Bausch + Lomb Infuse for Astigmatism Daily Disposable Contact Lenses	CI

Evolution of the average Target Price on Bausch + Lomb Corporation

Price target over the last 5 years

History of analyst recommendation changes

f65bd044d.iJiPzJTx6s4D2s8MOQQIzxUqj6glJcjpMINwVouratw.2d7FreK5qKZVla5vbVJ9-10Z3Z8UQaCfWOEdG_HcGLPG6eet2J2c9mSRgg~3e23abc16a597e1d4b9ce7825b1a4134

Analyst Recommendations on Bausch + Lomb Corporation

Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	05-06	MT
Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	05-06	MT
Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	05-02	MT
RBC Cuts Price Target on Bausch + Lomb to $18 From $20, Keeps Outperform Rating	04-22	MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	04-05	MT
Barclays Raises Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating	02-26	MT
Wells Fargo Ups Price Target on Bausch + Lomb to $23 From $21, Maintains Overweight Rating	02-22	MT
RBC Lifts Price Target on Bausch + Lomb to $20 From $19 After Better-Than-Expected Q4, Above-Consensus 2024 Revenue Guidance; Outperform Kept	02-22	MT
RBC Trims Price Target on Bausch + Lomb to $19 From $20 Ahead of Q4 2023 Report, Keeps Outperform Rating	02-09	MT
Evercore ISI Downgrades Bausch + Lomb to In Line From Outperform, Adjusts Price Target to $17 From $19	01-04	MT
Stifel Initiates Bausch + Lomb With Hold Rating, $16 Price Target	12-12	MT
Morgan Stanley Trims Price Target on Bausch + Lomb to $16 From $17, Maintains Equal-Weight Rating	12-04	MT
RBC Trims Price Target on Bausch + Lomb to $20 From $21 Amid Foreign-Exchange Headwinds, Keeps Outperform Rating	23/10/23	MT
Morgan Stanley Adjusts Price Target on Bausch + Lomb to $18.50 From $20, Keeps Equalweight Rating	13/10/23	MT
Barclays Adjusts Price Target on Bausch + Lomb to $19 From $18, Maintains Equalweight Rating	03/08/23	MT
RBC Lifts Price Target on Bausch + Lomb to $21 From $20 Ahead of Q2 Report, Maintains Outperform Rating	24/07/23	MT
BofA Securities Raises Price Target on Bausch + Lomb to $23 From $19, Maintains Buy Rating	03/07/23	MT
HC Wainwright Adjusts Price Target on Bausch + Lomb to $22 From $19, Keeps Buy Rating	19/05/23	MT
Barclays Adjusts Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating	05/05/23	MT
RBC Cuts Price Target on Bausch Health to $8 From $9, Notes Concerns for Ability to Distribute Bausch + Lomb Shares, Keeps Sector Perform Rating	05/05/23	MT
ANALYST RECOMMENDATIONS : Admiral, Alaska Air, KeyCorp, SVB Financial, United Airlines...	10/03/23
Needham & Co Initiates Bausch + Lomb Coverage With Hold Rating	09/03/23	MT
Needham Starts Bausch + Lomb at Hold	09/03/23	MT
HC Wainwright Adjusts Price Target on Bausch + Lomb to $21 From $20, Maintains Buy Rating	24/02/23	MT
Deutsche Bank Adjusts Bausch + Lomb's Price Target to $18 From $16, Maintains Hold rating	23/02/23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

14.89 USD

Average target price

18.71 USD

Spread / Average Target

+25.68%

High Price Target

25 USD

Spread / Highest target

+67.90%

Low Price Target

14 USD

Spread / Lowest Target

-5.98%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bausch + Lomb Corporation

Morgan Stanley
Deutsche Bank Securities
RBC Capital Markets
Barclays
Wells Fargo Securities
Evercore ISI
Stifel Nicolaus
BofA Securities
HC Wainwright
Needham & Co.
Goldman Sachs
Citigroup
Jefferies & Co.
Guggenheim
JPMorgan Chase
Cowen

Ratings for Bausch + Lomb Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar